Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: SCYNEXIS, Inc.

Market Cap 42.15M 36.44M 33.57M 31.44M 58.96M 4.01B 59.85M 398M 155M 1.95B 158M 155M 6.75B P/E Ratio 2026 *
-1.04x
P/E Ratio 2027 * -1.68x
Enterprise Value 42.15M 36.44M 33.57M 31.44M 58.96M 4.01B 59.85M 398M 155M 1.95B 158M 155M 6.75B EV / Sales 2026 *
36.5x
EV / Sales 2027 * 6.31x
Free-Float
97.9%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: SCYNEXIS, Inc.

1 day-0.35%
1 week-13.32%
Current month-25.00%
1 month-35.84%
3 months-40.72%
6 months-18.00%
Current year-16.39%
1 week 4.15
Extreme 4.15
4.81
1 month 4.15
Extreme 4.15
6.24
Current year 4.15
Extreme 4.15
9.12
1 year 4.15
Extreme 4.15
10.48
3 years 4.15
Extreme 4.15
30.96
5 years 4.15
Extreme 4.15
67.12
10 years 4.15
Extreme 4.15
440.8
Manager TitleAgeSince
Chief Executive Officer 61 01/01/2023
Director of Finance/CFO 65 24/10/2022
Chief Tech/Sci/R&D Officer - 01/10/2020
Director TitleAgeSince
Director/Board Member 73 01/12/2008
Chairman 67 04/06/2015
Director/Board Member 73 25/02/2015
Date Insider Type Main position Quantity % Market Cap.
04-01Buy

Chief Executive Officer

217,390 0.2736%
01-29Free

General Counsel

129,833 0.3094%
01-29Free

Chief Financial Officer

129,833 0.3094%
Change 5-day change 1-year change 3-year change Capi.($)
-0.35%-13.32%-40.23%-80.84% 42.15M
-2.41%+0.69%+40.12%+154.01% 1,035B
+1.07%+5.57%+55.14%+50.53% 574B
+1.32%+1.24%+18.92%+64.81% 397B
+0.77%+0.77%+21.19%+15.95% 324B
-0.85%-0.68%+23.44%+14.94% 281B
+0.44%+5.39%+25.86%+35.39% 278B
+1.66%+1.20%-44.41%-47.37% 193B
+0.32%+2.78%+21.72%+62.37% 191B
-0.22%-2.78%+14.90%+60.77% 156B
Average +0.11%+0.21%+13.67%+33.06% 343B
Weighted average by Cap. +0.15%+2.39%+28.93%+71.62%

Financials

2026 *2027 *
Net sales 1.15M 998K 919K 861K 1.61M 110M 1.64M 10.89M 4.23M 53.38M 4.33M 4.24M 185M 6.68M 5.77M 5.32M 4.98M 9.34M 635M 9.48M 63.01M 24.48M 309M 25.06M 24.52M 1.07B
Net income -41.07M -35.51M -32.71M -30.64M -57.45M -3.91B -58.32M -388M -151M -1.9B -154M -151M -6.58B -28.73M -24.84M -22.88M -21.43M -40.18M -2.73B -40.79M -271M -105M -1.33B -108M -106M -4.6B
Net Debt - -
Logo SCYNEXIS, Inc.
SCYNEXIS, Inc. is a biotechnology company focused on developing therapies to address severe rare diseases. The Company's SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. Its proprietary antifungal platform, fungerps, includes BREXAFEMME (ibrexafungerp tablets), which has been licensed to GSK, and SCY-247, which is in clinical stages of development. Its SCY-770 is a novel, highly selective, direct AMP-activated protein kinase (AMPK) activator for the treatment of ADPKD, a genetic cause of end-stage renal failure. Its SCY-770 is designed to address many of the underlying drivers of ADPKD by reducing cyst growth and disease progression. The United States Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC).
Employees
18
Date Price Change Volume
12/06/26 4.230 $ -0.35% 51,541
11/06/26 4.245 $ +2.29% 46,842
10/06/26 4.150 $ -4.82% 37,359
09/06/26 4.360 $ -2.02% 55,202
08/06/26 4.450 $ -5.52% 50,114
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
4.230USD
Average target price
33.55USD
Spread / Average Target
+693.07%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SCYX Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!